Loh, et al. compared with 80% for TEL/AML1-negative B-precursor patients (p=0.05). Five-year overall survival was 97% among TEL/AML-positive patients versus 89% among TEL/AML1-negative patients (p=0.03). However, in a multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment group, but not TEL/AML1 status, were found to be independent predictors of outcome. We conclude that TEL/AML1-positive patients have an excellent outcome, confirming our previous findings. However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients.
Introduction
The TEL/AML1 gene rearrangement results from a balanced, reciprocal, t(12;21)(p12;q22) and occurs in 25% of children with B-lineage acute lymphoblastic leukemia (ALL).
1,2 Current research focuses on determining the biologic function of the chimeric fusion protein, the cooperating events needed for leukemia development, the prognostic significance of this fusion gene, and the optimal therapy for these patients.
The TEL gene (also known as ETV6), first cloned in 1994 as a novel fusion partner to the PDGFRΒ receptor in a patient with chronic myelomonocytic leukemia 3 , is a member of the ETS family of transcription factors whose protein product is a nuclear phosphoprotein. 4 Tel deficiency in mice results in early embryonic lethality in part due to defective yolk sac angiogenesis and an inability to establish bone marrow hematopoeisis. 5 The TEL gene was subsequently described to partner with RUNX1 (also known as CBFA2 or AML1) in pediatric B-precursor cell ALL ( Figure 1 ). 6, 7 On of the most important predictors of failure in current risk models of ALL is the therapy received. 8 Identifying cohorts of patients who can be treated with specific combinations of therapy has been one of the key goals of current clinical trials. The detection of recurrent somatic cytogenetic abnormalities has allowed investigators to more accurately predict the outcome of patients sharing these events. For instance, it has been well established that ALL patients with the BCR-ABL gene rearrangement have a poor prognosis with standard ALL therapy and often require allogeneic transplant for optimal treatment. 9 Several retrospective studies have divergent results with respect to the prognostic significance of the TEL/AML1 fusion gene. 10 We previously reported that a subset of 22 TEL/AML1 positive patients treated on DFCI ALL Consortium protocols were 100% free of relapse with a median length However, subsequent reports noted that as many as 25% of children on BFM protocols who relapsed were TEL/AML1 positive. 12, 13 In addition, another cooperative group could not confirm that the TEL/AML1 fusion gene conferred a favorable prognosis. 14 Such differences in reported outcome may be explained by risk stratification and subsequent therapy received, and indicated that a prospective analysis of outcome was warranted.
In order to address potential selection biases from previous retrospective reports, we conducted a prospective study on the prognostic significance of the TEL/AML1 fusion gene in children enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01, a phase III clinical trial that accrued patients with newly diagnosed ALL. Protocol 95-01 stratified patients according to age and presenting white blood count using current NCI-Rome criteria, thereby eliminating risk stratification differences with many other cooperative groups.
Patients, material, and methods

Patients and leukemia samples
Diagnostic bone marrow and peripheral blood samples were collected prospectively from patients eligible to participate on DFCI ALL Consortium Protocol 95-01 between January 1996-September 2000. There were 491 patients enrolled on DFCI 95-01. For the purposes of this analysis, any bone marrow or peripheral blood sample falling within 5 days of the date of registration on study was considered to be diagnostic. Bone marrow or peripheral blood samples at diagnosis were obtained from 396 (81%) patients. Of the 396 patients, 352 had B-precursor ALL and 44 had T-cell ALL. Systemic therapy is summarized in 
Laboratory methods
After collection of bone marrow or peripheral blood, mononuclear cells were collected after density gradient centrifugation using Hypaque-Ficoll according to standard methods. A minimum of 5 million cells was placed either directly into RNA-Stat 60 (January 1996-November 1997), or RNEasy (Qiagen) or RNAqueous buffer (November 1997-2001) (Ambion). Total RNA was extracted according to the specific protocol and DNAsed with DNAse I (Ambion) followed by inactivation by DNAse Inactivator (Ambion). Total RNA was reverse transcribed into cDNA using standard methods. An aliquot of cDNA was then used in duplicate control PCR reactions to verify the integrity of the RNA sample using TEL specific primers 458 and 750R and were visualized on a 2.5% agarose gels as previously described 11, 15 . (Ambion). After an initial denaturing step at 95 degrees for 10 minutes, a two step PCR (95 degrees x 15 seconds followed by 60 degrees x 1 minute) was performed for forty cycles to amplify either a
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Products were visualized on agarose gels.
Statistical methods
Chi-square or, where cell frequencies were small, Fisher's exact tests were used to compare categorical variables between groups. Clinical and laboratory characteristics were categorized for analyses as shown in Table 2 . Event-free survival (EFS) was measured from date of complete remission at the end of induction therapy to the first of any event including induction failure, relapse, or death from any cause, or censored at last contact; induction failure and induction death were considered events at time zero. Overall survival was defined as the time from randomization to death, or censored at last contact. Survival distributions were estimated using the Kaplan-Meier method, and univariate associations were tested using log-rank tests. Cox proportional hazards regression was used to model the survival data on TEL/AML1 status while adjusting for known prognostic factors and treatment. Manual stepwise model selection was performed with Likelihood ratio tests using the variables in Table 2 ; all two-way interactions between variables in the final model were examined separately. Since white blood cell count (WBC) and age were found to be highly collinear with risk group, the final multivariable modeling used risk group and excluded WBC and age. All reported pvalues are from 2-sided tests, with 5% type I error rates. No adjustments were made for multiple comparisons. Analyses of the data set were current as of December 2004.
Results
Of the 491 eligible patients enrolled on Protocol 95-01, 396 (81%) had either a diagnostic peripheral blood or bone marrow sample obtained for TEL/AML1 analysis. There was no difference in positive. There were no significant differences between the clinical characteristics of patients who had a successful PCR and those who did not. Since none of the T-cell patients were TEL/AML1
positive, all analyses of the association of TEL/AML1 status with survival endpoints included only the 299 B-precursor patients with informative TEL/AML1 results. Table 2 outlines the clinical and laboratory characteristics for the B-precursor TEL/AML1 positive and negative patients at diagnosis.
As shown, TEL/AML1 positive and negative patients did not differ significantly with respect to any of these variables, with the exception of age (p=.05); TEL/AML1 positive patients were more likely to be between ages 1 and 10 years.
Two TEL/AML1 negative patients were lacking follow-up remission data and were excluded from all EFS analyses. With a median follow-up of 5. status with EFS. TEL/AML1 status was not associated with EFS within each risk group (p=0.14 for Moreover, within TEL/AML1 status groups, the type of asparaginase assigned was not significantly associated with EFS (p=0.80 comparing EFS between E.coli-and Erwinia-assigned TEL/AML1 positive patients subset and p=0.77 among the TEL/AML1 negative B-precursor patients).
In multivariable regression analyses examining the association of EFS with TEL/AML1
status and the other known prognostic factors and treatment groups shown in Table 1 , none of the following were statistically significant predictors of outcome: TEL/AML1 status, sex, CNS status, or race. When controlling for other significant predictors of EFS in the final model, risk group (p=0.009), and asparaginase treatment group (p= 0.04), but not TEL/AML1 status (p=0.12) were significantly associated with EFS. None of the interactions between these variables were significant, indicating that the effect of TEL/AML1 status on EFS did not differ within treatment or risk groups. However, the power for these comparisons was low. When WBC and age were included in the modeling instead of risk group, they were also highly statistically significant and overall results were quite similar. In all models, when controlling for risk group (or WBC and age), and asparaginase treatment group, the effect of TEL/AML1 on EFS was not statistically significant.
Discussion
One of the most important prognostic factors for patients with ALL in the current era is the intensity of treatment received. 16 One of the major determinants of treatment received is the assignment of patients to risk groups at diagnosis. The criteria used to assign patients to groups stratified according to risk have varied among national and international cooperative groups. In 1995, the Cancer Treatment and Evaluation Program gathered investigators to discuss unifying the approach to risk stratification, thus increasing the efficiency of clinical research in ALL. 17 In
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Therefore when the outcome data for patients who have TEL/AML1 positive leukemia is interpreted, it is crucial to assess risk stratification and subsequent dose intensity received. The heterogeneity of reported outcomes of TEL/AML1 positive patients can be analyzed within this context. For instance, DFCI ALL Consortium protocols before 1995 used more stringent criteria for defining lower risk patients (Standard risk= age, 2 through 9 years; presenting WBC count <20,000/mm 3 ; no CNS 2 or 3 disease; lack of T-cell immunophenotype, and lack of anterior mediastinal mass). 11, 15 All other patients were considered to be at high risk of relapse and received intensive therapy, including a higher cumulative dose of anthracycline and, often, cranial radiation.
In fact, half of the TEL/AML1 positive patients in the first retrospective report from the DFCI, and many of the patients reported by St. Jude (who placed them in a higher-risk group in light of a diploid DNA index) received very intensive therapy, potentially explaining the superior outcomes for these groups. 19, 20 The mechanism for the increased sensitivity to asparaginase among TEL/AML1 positive lymphoblasts is unclear and does not appear to be related to the levels of asparagine synthetase, either at baseline or after exposure to the drug. 21 The favorable outcome of TEL/AML1 positive patients on DFCI ALL Consortium protocols may be due to the protracted use of asparaginase during intensification, as well as frequent pulses of vincristine and steroids during the two years of treatment. The exposure to weekly L-asparaginase during the intensification phase in DFCI clinical trials has been closely linked with event-free survival. 22, 23 In addition, investigators in POG reported that patients with TEL/AML1-positive leukemia accumulate lower amounts of methotrexate polyglutamates; such a decrease has led to the speculation that these patients may be better treated by the increased doses of methotrexate used in these protocols. 24 In the present report, there was no difference in EFS among patients who were TEL/AML1
positive with respect to the type of asparaginase preparation received. Erwinia asparaginase has a shorter half-life than E. coli asparaginase, and has been associated with higher relapse rates when used instead of E. coli asparaginase. 25 Similarly, when analyzing all children enrolled on Protocol 95-01, Erwinia asparaginase was associated with an inferior EFS. 26 The lack of association between outcome and type of asparaginase used in TEL/AML1 positive patients supports that these patients have an increased sensitivity to asparaginase, resulting in adequate treatment even when a less effective preparation is used.
A third factor to consider when evaluating the outcome of TEL/AML1 positive patients is that relapsed disease might represent a novel "secondary" TEL/AML1 positive leukemia in which the original, pre-leukemic cell of origin was not completely eradicated by upfront chemotherapy. In support of this possibility, studies demonstrating the presence of low levels of the TEL/AML1 fusion gene in bloodspots from newborns who later developed leukemia establish that the initiating event of
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29
Analysis of relapsed cohorts of patients with TEL/AML1 positive leukemia indicate that patients remain sensitive to the same chemotherapeutic agents used at initial diagnosis. 30 Using microsatellite markers to study TEL gene rearrangements, immunoglobulin or TCR rearrangements,
and FISH analysis, a number of patients experiencing late relapses had TEL/AML1 positive leukemia derived from but not identical to the dominant clone at diagnosis. 31, 32 In addition, at least one patient who experienced a relapse during therapy acquired microsatellite instability in the relapsed subclone of the original leukemia. Taken together this data supports the hypothesis that preleukemic cells harboring the TEL/AML1 fusion gene are not eradicated by initial therapy in some patients who later relapse. A second, independent transforming event may then occur to give rise to another TEL/AML1-positive leukemia, which is still marked by an excellent response to chemotherapy.
In summary, we have confirmed in a prospective analysis that the TEL/AML1 fusion gene occurs in approximately 26% of pediatric patients with B-precursor ALL, and that these patients have excellent outcomes with currently available therapy from the DFCI ALL Consortium. The longer time to relapse for TEL/AML1 positive patients is consistent with other reports and the excellent overall survival of these patients in this study suggests that those who relapse can be salvaged. Our results indicate that presenting age and leukocyte count, and not TEL/AML1 status, were independent predictors of outcome, suggesting that NCI-Rome risk group status should be considered when treating TEL/AML1 positive patients. Because the association of TEL/AML1 status with EFS was a secondary objective, this study was not designed to guarantee sufficient power for examination of this 
